Skip to content

Materia and Sigma Aldrich Extend Catalyst Distribution Agreement

PASADENA, CA––(Marketwire) – August 16, 2012. Materia announced today a ten year extension of its exclusive catalyst distribution agreement with Sigma-Aldrich Corporation (Nasdaq:SIAL), that allows Aldrich Chemical Co. LLC to continue its worldwide rights to distribute the Materia Grubbs Catalyst™ technology to the research and development community.

“Sigma-Aldrich is the clear global leader in research chemical distribution,” stated John Kibler, Materia Vice President of Business Development – Grubbs Catalyst Technology. “Their strong channels provide innovators in the chemical, polymer, and pharmaceutical industries with straightforward catalyst access, which in turn enables a robust pipeline of win-win opportunities.”

Aldrich Chemical Co. LLC currently sells fifteen Materia metathesis catalysts (www.sigma-aldrich.com/metathesiscatalysts), which are based upon core patents exclusively licensed from the California Institute of Technology, as well as complementary technology from Materia, Boston College, the University of Calgary, and the University of New Orleans. The companies will launch a new metathesis catalyst providing cis-selectivity later this year.

About Materia
Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize-winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. Metathesis has been accepted as an emerging “green technology” platform and has been broadly adopted by the pharmaceutical, chemical, and polymer industries. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, “metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment.” For more information, visit: www.materia-inc.com.

For further information please contact:

Tom Buel
Director of Communications
Materia, Inc.
(626) 584-8400

Materia Announces NIH Phase II Funding

PASADENA, CA–(Marketwire – May 1, 2012) – Materia announced today the receipt of a Phase II Fast Track Small Business Technology Transfer grant from the National Institutes of Health (NIH) for the continued development of functional polymers for use in organic synthesis.

The new Phase II program, which furthers the Phase I joint effort between Materia and Professor Paul Hanson of the University of Kansas, will focus on polymer process development and scale-up as well as beta testing by key industrial collaborators.

“Materia appreciates NIH’s vision and continued support,” stated Dr. Michael Giardello, Materia’s Chief Executive Officer. “These materials provide higher functional group content, reduced swelling, and enhanced solvent compatibility versus state-of-the-art polystyrene-bound reagents, and their commercialization may ultimately expedite the timeframe at which new therapeutic agents become available to consumers.”

“We are excited and honored at our continued collaboration with Materia, Inc. which will enable further development of this new and challenging science,” added Professor Hanson. “Materia’s expertise in polymerization, scale up and commercialization will drive efforts moving forward.”

About Materia
Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize-winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. Metathesis has been accepted as an emerging “green technology” platform and has been broadly adopted by the pharmaceutical, chemical, and polymer industries. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, “metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment.” For more information, visit www.materia-inc.com.

About the University of Kansas Chemical Methodologies and Library Development Center (KU-CMLD)
The NIH Center in Chemical Methodologies and Library Development (CMLD, Jeffrey Aubé, PI, Medicinal Chemistry) is a multidisciplinary initiative established in 2003 to enable the development of new chemical methodologies to enhance projects directed at library synthesis. Current focus includes the broad areas of microwave-assisted flow synthesis, methods for complex scaffold synthesis, organometallic parallel synthesis and the preparation of libraries based on natural products.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.

For further information please contact:

Tom Buel
Director of Communications
Materia, Inc.
(626) 584-8400

Patents for Improved Metathesis Catalysts Issued to Materia/Caltech

PASADENA, CA––(Marketwire – November 8, 2011) – Materia, Inc. announced today that the United States Patent and Trademark Office has issued patent No: US 8,008,224 and No: US 8,039,566 entitled “Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins” and “Olefin Metathesis Initiators Bearing Thiazol-2-ylidene ligands,” respectively. The patents cover a new series of ruthenium organometallic complexes which have outstanding reactivity profiles and are the results of collaborative research between Materia and the California Institute of Technology.

The novel ruthenium complexes demonstrate excellent catalytic activity for the metathesis of hindered olefins, a challenging category of olefins to access with previously reported catalysts. The new catalysts enable metathesis approaches for the synthesis of an expanded class of compounds in the pharmaceutical and specialty chemical industries.

Research quantities of Materia’s metathesis catalysts are available from Sigma-Aldrich Corporation or in larger quantities directly from Materia. Technical information on ruthenium metathesis catalysts and their use can be found on Materia’s All Things Metathesis blog at http://allthingsmetathesis.com.

“We are excited to advance and expand the applicability of olefin metathesis in organic synthesis,” said Dr. Michael Giardello, Materia’s Chief Executive Officer. “These patents validate Materia’s position as the world innovator in metathesis technologies through the continued cooperation of Caltech and Materia.”

“It is important for new discoveries to be available for everyone to use and it is exciting that Materia is making these new catalysts available so that the community can exploit the new metathesis capabilities to solve challenging synthetic problems,” stated Nobel Laureate Professor Robert H. Grubbs, of the California Institute of Technology.

These newly issued patents add to the collection of over 350 patents in Materia’s portfolio which protects the intellectual property around the processes and catalysts that enable successful metathesis reactions and create innovative solutions for the global chemical industry.

About Materia
Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize-winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. Metathesis has been accepted as an emerging “green technology” platform and has been broadly adopted by the pharmaceutical, chemical, and polymer industries. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, “metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment.” For more information, visit www.materia-inc.com.

Materia Announces NIH Award for Further Development of Drug Discovery Reagents

PASADENA, CA––(Marketwire – June 7, 2011) – Materia announced today the funding of a Phase I Fast Track Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) for the development of reagent and scavengers for use in high throughput chemistry. The proposed reagents will offer numerous benefits to the drug discovery industry. Read more

Materia Announces Plans for Singapore-based Catalyst Manufacturing Facility

PASADENA, CA––(Marketwire – March 16, 2011) – Materia announced today its plans for opening a catalyst manufacturing and R&D facility in Singapore. The company expects to complete the site selection process in 3Q 2011 and begin construction by year-end. Read more